We are pleased to share that Ms. Jennifer Che, our President and Managing Director, has once again been recognized in the IAM Strategy 300: The World’s Leading IP Strategists. This repeated honor reflects Jennifer’s outstanding strategic insight, deep expertise in intellectual property, and continued leadership in helping clients develop and implement IP strategies that create long-term value.  


The IAM Strategy 300 is a guide to the pioneers in the industry. It recognizes individuals who are “leading the way in developing and implementing strategies that maximize the value of IP portfolios.” Individuals are nominated by the community, and only those identified by market sources for their “exceptional skill sets and profound insights into patent matters” are featured in the IAM Strategy 300. Jennifer's consecutive inclusion on this list demonstrates her exceptional IP expertise, strategic insight, and dedicated commitment to driving long-term value for clients.


With a robust 20-year career as a scientist, patent attorney, and executive, Jennifer has helped numerous companies, institutions, inventors, and start-ups devise effective global intellectual property (IP) strategies. She excels at crafting integrated IP solutions that involve technical, regulatory, and long-range business needs. Jennifer's extensive experience in the U.S. and Greater China gives her a distinctive strategic eye for navigating complex cross-border IP challenges.


Please join us in congratulating Jennifer on this distinguished honor.

Best regards,

Eagle IP

我們過去活動

Recommended Insights

Diagnostic Claims in China

2020年1月9日
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]

Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data

2026年1月23日
On December 31, 2025, The Supreme People's Court upheld the Beijing IP Court's decision, meaning that the semaglutide patent remains valid and will expire on March 20, 2026. Novo Nordisk announced this positive news via a press release on the day the case was decided. The Chinese Ministry of Commerce has also confirmed this decision […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

2024年2月28日
A Closer Look at the New Presumed Receipt Date Calculation Background China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]
Top crossarrow-right